AB1165 THE MINIMAL CLINICALLY IMPORTANT DIFFERENCE (MCID) RAISES THE SIGNIFICANCE OF OUTCOME EFFECTS ABOVE THE STATISTICAL LEVEL
Background: In measurement of outcome effects, the patient's subjective perception to feel a change in health defines clinical effectiveness irrespective of statistical significance. Nevertheless, many -especially pharmacologicalstudies argue with statistical effects alone. Objectives: To review, develop, illustrate, and discuss current and proposed new concepts of effect quantification and significance. Methods: Different methods for determining minimal clinically important differences (MCIDs) were reviewed and further developed focusing on their characteristics and (dis)advantages. The concepts were illustrated by empiric rehabilitation effects (evaluation study) and a randomized controlled trial (investigative study) in knee osteoarthritis.
Results:
In controlled studies, empirical score differences between verum and placebo become statistically significant if sample sizes are sufficiently large. For example, a score difference of 5 points (scale 0-100) between the verum and the placebo effect becomes statistically significant, if the sample sizes are n≥33 for each of both groups at a standard deviation=10 of the score differences (baseline to follow-up). MCIDs by contrast, are defined by patients' perceptions, which led to "anchoring" of effects by the "transition" item, where patients rate their change of health between baseline and follow-up in an evaluation study. The MCID for improvement by the "mean change method" is the difference of the mean change experienced by the "slightly better" group minus that of the "almost equal" group. The MCID can be expressed as absolute or relative score, as effects size (ES), standardized response mean (SRM) and standardized mean difference (SMD) (bivariate). It can further be adjusted by multivariate regression modeling. In our example of knee osteoarthritis, the MCID for pain relief was 8.74 score points (scale 0-100), 17.15% of the baseline score, ES=0.407, SRM=0.413, SMD=0.469. This is consistent to the range of 0.30-0.50 for MCIDs reviewed in literature. After adjusting for potential confounders, the MCID was 7.09 score points or an increase of 2.9% per score point to feel better obtained by logistic regression. Conclusions: Absolute and relative MCIDs are easy to interpret and apply to data of investigative studies. MCIDs expressed as ES/SRM/SMD reduce bias, which mainly results from dependency on the baseline score. Multivariate linear and logistic regression modeling further reduces bias by adjustment for possible confounders and increase validity. Anchor-based methods use clinical/subjective perception to define MCIDs and should be clearly differentiated from distributionbased methods that provide statistical effect significance only. [2] . Adalimumab (ADA) is a human monoclonal antibody directed against TNFα and is highly effective in the treatment of RA. For efficient treatment trough levels of ADA need to be adjusted within a therapeutic window which is 5 to 10 μg/mL [3] . A rapid test allows faster reporting of trough levels, providing a great advantage over test formats that need samples to be sent to a central or service laboratory. Here we report on the technical performance evaluation of the Quantum Blue ® Adalimumab lateral flow test. Objectives: Development and performance evaluation of a rapid test for the monitoring of ADA trough levels in human serum at the point of care. Methods: The sandwich lateral flow immunoassay uses a TNFα coated gold label and a highly specific monoclonal antibody immobilized on the test membrane to detect ADA in diluted human serum samples. Sensitivity of the assay was determined by calculating limit of detection (LoD) and limit of quantification (LoQ) according to CLSI EP17-A2 guideline. Moreover, the assay was evaluated regarding cross-reactivity with other therapeutic antibodies targeting TNFα, influence of rheumatoid factors (RF) and high dose hook effect. A method comparison was performed against a commercially available ELISA (RIDASCREEN ® ADM Monitoring, R-Biopharm, Germany) to compare the trough level results of 40 patients treated with ADA. All statistical analyses were performed with Analyse-it for Excel. Results: The Quantum Blue ® Adalimumab test allowed analysis of serum samples within 15 minutes. The samples were diluted 1:20 in chase buffer before application onto a test cassette (volume 80 μL). The readout was performed with the Quantum Blue ® Reader resulting in adalimumab concentration levels in the lower μg/mL range. The test exhibited a LoD of 0.2 μg/mL and a LoQ of 0.69 μg/mL. No high dose hook effect was detected for samples containing up to 1000 μg/mL ADA. The latter two data sets allowed a measuring range of 1 to 35 μg/mL of ADA in patient samples. Other therapeutic TNFα blockers, like infliximab and golimumab, showed no cross-reactivity with the Quantum Blue ® Adalimumab test. RF showed no influence on correct measurement of ADA at all tested concentrations. The method comparison to a well-established commercial ELISA method revealed a slope of 1.12 and a regression coefficient (r 2 ) of 0.90 (by Passing-Bablok). A Bland-Altman analysis showed a bias of 1.9% confirming the overall excellent correlation of the two methods as well as the accuracy of our newly developed rapid test. Conclusions: The BÜHLMANN Quantum Blue ® Adalimumab assay enables the quantitative determination of ADA trough levels over the clinically relevant range in serum with a time to result of only 15 minutes. The assay exhibits an excellent accuracy and correlation to a well-established laboratory reference method. Hence, it represents a valuable tool for the clinician to assess the trough levels during ADA treatment follow up at the point of care. Background: Previous studies have indicated that anti-citrullinated protein antibody (ACPAs) titers are associated with the presence and severity of interstitial lung disease (ILD) in RA. The lung might be a site of initiation of immunity to citrullinated proteins. Previous studying anti-citrullinated HSP90 (citHSP90β) profiles between bronchial veolarlavage fluid (BALF) and serum indicated the lung plays a direct role in shaping the immune repertoire of RA-ILD. Objectives: Whether citHSP90β contributes to the initiation or perpetuation of autoimmune interstitial lung abnormalities (ILA) in RA remains to be clarified. To address this issue we investigated the spontaneous T cell responses to the putative autoantigen citrullinated HSP90β in different stages of RA-ILD. Methods: In RA-no ILD (n=19), indeterminate ILD (ILA1) (n=24), subclinical RA-ILD (ILA 2) (n=20), clinical RA-ILD (ILA3) (n=4) and other connective tissue disease associated ILD (CTD-ILD) (n=14) patients. Cultures derived from whole blood were individually stimulated with HSP90β, citHSP90β, citrullinated BSA, or no antigen. The concentration of 13 cytokines and chemokines in the plasma supernatant were then measured using Luminex xMAP technology. Results: CitHSP90β induced significantly higher levels of IFN-γ levels in RA-ILD (ILA=2+3) groups compared to the RA-no ILD group (p=0.002), but did not stimulate the production of other cytokines (p>0.05). Furthermore, citHSP90β did not stimulate the production of IFN-γ or other cytokines stimulated those individuals with non-RA CTD-ILD (p=0.1039, IFN-g). Background: Patient reported outcomes PRO are a key element in the global evaluation of patients, especially those followed in a day hospital. The use of touchscreen computers is one of the new features in the day hospital of Instituto Português de Reumatologia. Objectives: to evaluate the transition from paper to touchscreen computers technology of the PRO in use in Reuma.pt Methods: We considered a step up model of comparison with 2 months intervals one before the use of the touchscreen computers, one two months after the introduction of touchscreen computers and a third after an intermediate evaluation (comparison between interval 0 and 1) of the results.A specific formation to physicians and nurses to be aware of missing data from non-total completion of the questionnaires was introduced between the first and second evaluation. The percentage of questionnaires totally completed by number of patients were obtained for every period and diagnosis Results: 631 day hospital appointments were evaluated according to diagnosis and interval and the percentage was obtained (Table 1) . The mRNA expression of FcγRIIB was measured using real-time PCR. We examined the relationship between FcγRIIB expression and clinical features. Results: The expression of FcγRIIB on SSc naïve B cells and DN memory B cells was significantly stronger than that on the B cells of healthy subjects ( Figure  1 ) (p<0.05 and p<0.001, respectively). FcγRIIB mRNA expression on SSc B cells was also significantly stronger than that on the B cells of healthy subjects (p<0.01). The expression of CD80, CD86, and CD95, activation markers on B cells, was stronger in all 5 B cell subsets, except for CD80 in switched memory B cells and plasmablasts. Patients with the stronger expression of FcγRIIB on DN memory B cells more frequently had interstitial lung disease than those with normal levels (p<0.05). Cyclophosphamide pulse therapy significantly reduced the expression of FcγRIIB on preswitched memory B cells and switched memory B cells (p<0.05 and p<0.05, respectively).
Conclusions

